Answers are grounded in this paper and cite their sources.
Cost-effectiveness analysis compares nivolumab plus ipilimumab with alternative treatments in hepatocellular carcinoma, suggesting economic considerations for healthcare payers.
Nivolumab plus ipilimumab is unlikely to be cost-effective as first-line therapy for unresectable HCC from US health care payer perspective. However, extended dosing interval or price reductions may render the regimen economically viable, with important implications for clinical practice, payers, and policy.
No takes yet. Share an insight, caveat, or question.
Luo et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: